EP1986690A4 - Antikörper gegen fcrn zur behandlung von auto-/alloimmunleiden - Google Patents

Antikörper gegen fcrn zur behandlung von auto-/alloimmunleiden

Info

Publication number
EP1986690A4
EP1986690A4 EP07762598A EP07762598A EP1986690A4 EP 1986690 A4 EP1986690 A4 EP 1986690A4 EP 07762598 A EP07762598 A EP 07762598A EP 07762598 A EP07762598 A EP 07762598A EP 1986690 A4 EP1986690 A4 EP 1986690A4
Authority
EP
European Patent Office
Prior art keywords
allo
auto
treatment
immune conditions
fcrn antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07762598A
Other languages
English (en)
French (fr)
Other versions
EP1986690A2 (de
Inventor
Joseph P Balthasar
Ryan J Hansen
Jin Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/634,676 external-priority patent/US7662928B2/en
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of EP1986690A2 publication Critical patent/EP1986690A2/de
Publication of EP1986690A4 publication Critical patent/EP1986690A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP07762598A 2006-01-25 2007-01-23 Antikörper gegen fcrn zur behandlung von auto-/alloimmunleiden Withdrawn EP1986690A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76215106P 2006-01-25 2006-01-25
US11/634,676 US7662928B2 (en) 2003-08-08 2006-12-06 Anti-FcRn antibodies for treatment of auto/allo immune conditions
PCT/US2007/001742 WO2007087289A2 (en) 2006-01-25 2007-01-23 Anti-fcrn antibodies for treatement of auto/allo immune conditions

Publications (2)

Publication Number Publication Date
EP1986690A2 EP1986690A2 (de) 2008-11-05
EP1986690A4 true EP1986690A4 (de) 2009-05-13

Family

ID=39791300

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07762598A Withdrawn EP1986690A4 (de) 2006-01-25 2007-01-23 Antikörper gegen fcrn zur behandlung von auto-/alloimmunleiden

Country Status (4)

Country Link
EP (1) EP1986690A4 (de)
JP (1) JP2009524664A (de)
CA (1) CA2637929A1 (de)
WO (1) WO2007087289A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
AU2015200004B2 (en) * 2008-04-25 2017-02-16 Bioverativ Therapeutics Inc. Antibodies against fcrn and use thereof
WO2009131702A2 (en) * 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
AU2012262007B2 (en) 2011-06-02 2017-06-22 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
PL3137504T3 (pl) 2014-04-30 2023-10-16 Hanall Biopharma Co., Ltd. Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
EP3294335B1 (de) 2015-05-12 2023-07-05 Syntimmune Inc. Humanisierte affinitätsgereifte anti-fcrn-antikörper
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
SMT202400004T1 (it) 2016-07-29 2024-03-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo
MA49378A (fr) * 2017-06-15 2020-04-22 UCB Biopharma SRL Méthode de traitement de la thrombocytopénie immunitaire
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013912A2 (en) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions
WO2006118772A2 (en) * 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043658A2 (en) * 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013912A2 (en) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions
WO2006118772A2 (en) * 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AKILESH SHREERAM ET AL: "The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328 - 1333, XP002417288, ISSN: 0021-9738 *
HANSEN R J ET AL: "Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia", JOURNAL OF PHARMACEUTICAL SCIENCE, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON.; US, vol. 92, no. 6, 1 June 2003 (2003-06-01), pages 1206 - 1215, XP009109898, ISSN: 0022-3549 *
RAGHAVAN M ET AL: "ANALYSIS OF THE PH DEPENDENCE OF THE NEONATAL FC RECEPTOR/IMMUNOGLOBULIN G INTERACTION USING ANTIBODY AND RECEPTOR VARIANTS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 34, no. 45, 1 January 1995 (1995-01-01), pages 14649 - 14657, XP009044243, ISSN: 0006-2960 *
RAGHAVAN MALINI ET AL: "The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release", BIOCHEMISTRY, vol. 32, no. 33, 1993, pages 8654 - 8660, XP002520215, ISSN: 0006-2960 *
STORY C M ET AL: "A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-LIKE FC RECEPTOR CLONED FROM HUMAN PLACENTA: POSSIBLE ROLE IN TRANSFER OF IMMUNOGLOBULIN G FROM MOTHER TO FETUS", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 180, 1 December 1994 (1994-12-01), pages 2377 - 2381, XP002943093, ISSN: 0022-1007 *
YU ET AL: "MECHANISM OF INTRAVENOUS IMMUNE GLOBULIN THERAPY IN ANTIBODY-MEDIATED AUTOIMMUNE DISEASES", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 340, no. 3, 21 January 1999 (1999-01-21), pages 227/228, XP008055851, ISSN: 0028-4793 *

Also Published As

Publication number Publication date
CA2637929A1 (en) 2007-08-02
JP2009524664A (ja) 2009-07-02
WO2007087289A2 (en) 2007-08-02
EP1986690A2 (de) 2008-11-05
WO2007087289A3 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
EP1986690A4 (de) Antikörper gegen fcrn zur behandlung von auto-/alloimmunleiden
LTC2662091I2 (lt) Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
EP1898930A4 (de) Behandlung von entzündlichen erkrankungen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1793858A4 (de) Menschliche monoklonale anti-ctla4-antikörper zur krebsbehandlung
EP2014514A4 (de) Bodenabstandsstück für fahrzeug
EP2194066A4 (de) Modifizierte konstante antikörperregion
EP2020970A4 (de) Augenbehandlung
EP2376656A4 (de) Verfahren und bestimmung der wirksamkeit einer glucocorticoidbehandlung von eosinophiler ösophagitis
EP2385114A4 (de) Krebsbehandlungsdiagnose mit anti-tm4sf20-antikörper
EP2117479A4 (de) Immobilisierung des iliosakralgelenks
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
EP2063889A4 (de) Spiropiperidin-beta-sekretase-hemmer zur behandlung der alzheimer-krankheit
EP1931691A4 (de) Odkase-inhibitoren zur behandlung von malaria
EP1765288A4 (de) Verfahren zur behandlung von endobronchialen infektionen
EP1880206A4 (de) Multiplex-einfang von nukleinsäuren
EP2337798A4 (de) Bsa-spezifische antikörper
EP1885400A4 (de) Verfahren zur behandlung von hirntumoren durch antikörper
EP2200443A4 (de) Verzweigtkettige fettsäuren für die vorbeugung oder behandlung von störungen des magen-darm-trakts
EP2207892A4 (de) Verfahren zur selektion aktiver agentien für die krebsbehandlung
EP1776136A4 (de) Behandlung von entmyelinisierenden erkrankungen
EP1943972A4 (de) Instrument für die endoskopische behandlung
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
EP2219666A4 (de) Prostata-säure-phosphatase zur behandlung von schmerzen
EP2296665A4 (de) Pharmazeutische zusammensetzung zur behandlung von vorzeitiger ejakulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080822

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20081009

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/563 20060101ALI20081105BHEP

Ipc: G01N 33/53 20060101ALI20081105BHEP

Ipc: C12P 21/08 20060101ALI20081105BHEP

Ipc: C07K 16/28 20060101ALI20081105BHEP

Ipc: A61K 39/395 20060101AFI20081105BHEP

Ipc: G01N 33/577 20060101ALI20081105BHEP

Ipc: G01N 33/564 20060101ALI20081105BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FENG, JIN

Inventor name: HANSEN, RYAN, J.

Inventor name: BALTHASAR, JOSEPH, P.

A4 Supplementary search report drawn up and despatched

Effective date: 20090417

17Q First examination report despatched

Effective date: 20090717

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091130